Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Neurology

• Publication date

  1989-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 2586764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Controlled‐release carbidopa/levodopa (CR4‐Sinemet) in Parkinson's disease patients with and without motor fluctuations

  1988cited by this paper
• Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.

  1988cited by this paper
• Controlled‐release levodopa/carbidopa.

  1987cited by this paper
• Parkinson's disease and motor fluctuations

  1987cited by this paper

• Parkinson's Disease

  2019cites this paper
• Natural Products Combating Neurodegeneration: Parkinson's Disease.

  2017cites this paper
• Ultrasound targeted CNS gene delivery for Parkinson's disease treatment

  2017cites this paper
• Characterization of Vesicular Monoamine Transporter 2 and its role in Parkinson's Disease Pathogenesis using Drosophila

  2016cites this paper
• Idiopathic parkinsons disease: epidemiology, diagnosis and management

  2006cites this paper
• Know thyself: autologous cell transplantation strategies for brain repair.

  2005cites this paper
• Chapter 74 – Parkinsonism

  2003cites this paper
• Parkinson’s Disease: A Review of Drug Trials

  2001cites this paper
• History of levodopa and dopamine agonists in Parkinson's disease treatment

  1998cites this paper
• Pharmacoeconomic Analysis of Using Sinemet CR over Standard Sinemet in Parkinsonian Patients with Motor Fluctuations

  1998cites this paper
• Positron emission tomography (PET) measurements of striatal D(2) receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET((R)) or SINEMET((R)) CR.

  1997cites this paper
• [Pharmacological therapy of complicated Parkinson's disease].

  1997cites this paper
• Positron Emission Tomography (PET) Measurements of Striatal D2 Receptors in Untreated Parkinson's Disease Patients with Follow-up after 6 and 12 Months' Treatment with SINEMET@ or SINEMET@ CR

  1997cites this paper
• [Physiopathology of the dyskinesias induced by L-dopa].

  1997cites this paper
• Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.

  1996cites this paper
• Adverse Reactions to Controlled Release Levodopa/Carbidopa in Older Persons: Case Reports

  1995cites this paper
• Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.

  1995cites this paper
• Idiopathic Parkinson's disease: epidemiology, diagnosis and management.

  1995cites this paper
• Therapeutic Advantages of Sustained Release Levodopa Formulations in Parkinson’s Disease

  1994cites this paper
• Problems with long-term levodopa therapy for Parkinson's disease.

  1994cites this paper
• Parkinson's disease.

  1994cites this paper
• Mid-stage parkinsonism with mild motor fluctuations.

  1994cites this paper
• Sleep in Parkinson's disease

  1993cites this paper
• Clinical experience with controlled‐release carbidopa/levodopa in Parkinson's disease

  1993cites this paper
• Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease

  1993cites this paper
• The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.

  1993cites this paper
• Treatment of Parkinson's disease.

  1993cites this paper
• Long‐acting carbidopa‐levodopa in the management of moderate and advanced Parkinson's disease

  1992cites this paper
• Sustained Release Antiparkinson Agents: Controlled Release Levodopa

  1992cites this paper
• Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR)

  1992cites this paper
• Long-Term Evaluation of Sinemet® CR in Parkinsonian Patients with Motor Fluctuations

  1991influential citation
• “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

  1991cites this paper
• Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.

  1991cites this paper
• Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)

  1990cites this paper
• The rabbit syndrome.

  1990cites this paper
• Levodopa therapy in Parkinson's disease

  1990cites this paper
• Parkinson's disease

  1940cites this paper